Citations

Clear

3057 citation(s) found for "Cd, Johnson".

P4–185: Patient survey of comprehensive dementia evaluation
Parfitt, Francine, Fletcher, Rita, Graff‐Radford, Neill R., Johnson, Heather K.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_18 | Pages: No page available

10.1016/j.jalz.2006.05.1924 Get It

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
Lynch, Thomas J. , Adjei, Alex A. , Bunn, Paul A. , Engelman, Jeffrey A. , Haber, Daniel A. , Heymach, John V. , Jänne, Pasi A. , Johnson, Bruce E. , Johnson, David H. , Lilenbaum, Rogério, Sandler, Alan B., Sequist, Lecia V. , Settleman, Jeffrey , Wong, Kwok‐Kin , Hart, Carol S. , Eisen, Tim G , Goss, Glenwood D. , Meyerson, Matthew , Heymach, John V

Mayo Clinic

Clinical Cancer Research | July 20, 2006 | Volume: 12 | Issue: 14 | Pages: 4365s-4371s

10.1158/1078-0432.ccr-06-1005 | PMID 16857812 Get It

Cognitive Rehabilitation Interventions for Executive Function: Moving from Bench to Bedside in Patients with Traumatic Brain Injury
Cicerone, Keith D. , Levin, Harvey S. , Malec, James F. , Stuss, Donald T. , Whyte, John

Mayo Clinic

Journal of Cognitive Neuroscience | July 13, 2006 | Volume: 18 | Issue: 7 | Pages: 1212-1222

10.1162/jocn.2006.18.7.1212 | PMID 16839293 Get It

Abstract Executive function mediated by prefrontally driven distributed networks is frequently impaired by traumatic brain injury (TBI) as a result of diffuse axonal injury and focal lesions. In addition to executive cognitive functions such as planning and working memory, the effects of TBI impact social cognition and motivation processes. To encourage application of cognitive neuroscience methods to studying recovery from TBI, associated reorganization of function, and development of interventions, this article reviews the pathophysiology of TBI, critiques currently employed methods of assessing executive function, and evaluates promising interventions that reflect advances in cognitive neuroscience. Brain imaging to identify neural mechanisms mediating executive dysfunction and response to interventions following TBI is also discussed.
Parkinson disease
Uitti, Ryan J. , Baba, Yasuhiko , Whaley, Nathaniel R., Putzke, J. D., Wszołek, Zbigniew K.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 64 | Issue: 11 | Pages: 1925-1930

10.1212/01.wnl.0000163993.82388.c8 | PMID 15955945 Get It

Patient Outcomes After Vestibular Schwannoma Management: a Prospective Comparison of Microsurgical Resection and Stereotactic Radiosurgery
Pollock, Bruce E. , Driscoll, Colin L. W., Foote, Robert L. , Link, Michael J. , Gorman, Deborah A., Bauch, Christopher D., Mandrekar, Jayawant N. , Krecke, Karl N. , Johnson, C. H.

Mayo Clinic

Neurosurgery | July 6, 2006 | Volume: 59 | Issue: 1 | Pages: 77-85

10.1227/01.neu.0000219217.14930.14 | PMID 16823303 Get It

Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population
Joshi, Nina, Johnson, Laura Lee , Wei, Wenqiang , Abnet, Christian C. , Dong, Zhiwei , Hawk, Ernest T. , Qiao, You‐Lin , Taylor, Philip R. , Limburg, Paul J. , Dawsey, Sanford M. , Kirsch, Ilan R. , Abnet, Christian C

Mayo Clinic

Cancer Research | July 6, 2006 | Volume: 66 | Issue: 13 | Pages: 6851-6860

10.1158/0008-5472.can-06-0662 | PMID 16818663 Get It

AbstractA randomized, double-blinded, placebo-controlled 2 × 2 factorial chemoprevention trial was conducted in Linxian, China to assess the effects of selenomethionine and celecoxib on the natural history of esophageal squamous dysplasia. Results from this study indicated that asymptomatic adults with mild dysplasia were more likely to show an improvement when treated with selenomethionine compared with placebo (P = 0.02). Prompted by this finding, we examined the molecular profiles associated with regression and progression of dysplastic lesions in normal mucosa from 29 individuals, a subset of the Linxian cohort, using the Affymetrix U133A chip. Twenty differentially expressed genes were associated with regression and 129 were associated with progression when we compared the change in gene expression over time. Genes associated with immune response (n = 15), cell cycle (n = 15), metabolism (n = 15), calcium transport or calcium ion activity (n = 10), regulation of transcription (n = 9), signal transduction (n = 7), cytoskeleton and microtubules (n = 5), nucleotide processing and biosynthesis (n = 4), G-coupled signaling (n = 4), and apoptosis (n = 3) were present in the list of 149 genes. Using the Expression Analysis Systematic Explorer pathway analysis program, only the immune response pathway was significantly overrepresented among these 149 genes. Individuals whose lesions regressed seemed to have higher expression of genes associated with immune stimulation, such as antigen presentation, survival of T cells, and T-cell activation (HLA-DRA, HLA-DPA1, HLA-DBQ1, CD58, and FCER1A). In contrast, individuals whose lesions progressed had higher expression of genes involved in immune suppression and inflammation (CNR2, NFATC4, NFRKB, MBP, INHBB, CMKLR1, CRP, ORMS, SERPINA7, and SERPINA1). These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia. (Cancer Res 2006; 66(13): 6851-60)
Primary reticulum‐cell sarcoma of bone
McCormack, Lawrence J., Ivins, John C., Dahlin, David C., Johnson, Einer W.

Mayo Clinic

Cancer | June 24, 2006 | Volume: 5 | Issue: 6 | Pages: 1182-1192

10.1002/1097-0142(195211)5:6<1182::aid-cncr2820050615>3.0.co;2-# | PMID 12998025 Get It

Quality of Life of Caregivers of Patients With Advanced-Stage Cancer
Clark, Matthew M. , Rummans, Teresa A. , Sloan, Jeff A. , Jensen, Andrus, Atherton, Pamela J. , Frost, Marlene H., Richardson, Jarrett W., Bostwick, John , Hanson, Jean, Brown, Paul D. , Johnson, Mary E.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | June 15, 2006 | Volume: 23 | Issue: 3 | Pages: 185-191

10.1177/1049909106289074 | PMID 17060277 Get It

There has been much research documenting the impact of having a loved one diagnosed with advanced cancer, but little is known about how to reduce care-giver burden. In this randomized controlled trial, the authors examined the potential relationship of an advanced cancer patient’s participation in an 8-session, structured, multidisciplinary intervention on the care-giver’s burden and quality of life (QOL). Although the patients randomly assigned to the intervention (n = 54) demonstrated improved QOL compared to the control condition (n = 49) participants ( P < .05), there was no evidence that improving the patient’s QOL made an impact on the caregiver’s level of burden or the care-giver’s QOL. Further investigation is warranted in this area, including interventions specifically designed and targeted to both reduce caregiver burden and to improve caregiver QOL.
Impact of Transforming Growth Factor-β1 on Atrioventricular Node Conduction Modification by Injected Autologous Fibroblasts in the Canine Heart
Bunch, T. Jared , Mahapatra, Srijoy, Bruce, G. Keith, Johnson, Susan B., Miller, Dylan V. , Horne, Benjamin D. , Wang, Xiao-Li, Lee, Hon-Chi, Caplice, Noel M. , Packer, Douglas L. , Wang, Shaohua , Wang, Xiao-Li

Mayo Clinic

Circulation | May 23, 2006 | Volume: 113 | Issue: 21 | Pages: 2485-2494

10.1161/circulationaha.105.570796 | PMID 16717152 Get It

Background— Atrioventricular (AV) nodal ablation for management of atrial fibrillation (AF) is irreversible and requires permanent pacemaker implantation. We hypothesized that as an alternative, implantation of autologous fibroblasts in the perinodal region would focally modify AV nodal conduction and that this modulation would be enhanced by pretreatment with transforming growth factor-β1 (TGF-β1), a stimulant of fibroblasts. Methods and Results— Skin biopsies were taken from 12 mongrel dogs, and derived fibroblasts were dissociated and grown in culture for 2 weeks. Multiple injections (0.25 mL) were made through an 8F NOGA catheter along the fast/slow AV nodal pathways as guided by an electroanatomic mapping system. Seven dogs received fibroblasts alone (1×10 6 cells/mL), 7 dogs received TGF-β1 (5 μg), 4 dogs received fibroblasts and TGF-β1 (1×10 6 cells/mL+5 μg), and 4 dogs received saline only. AV node function was assessed at baseline and after 4 weeks. Saline (80 mL) with assigned therapy (0.25 mL per injection) was injected into the peri-AV nodal region in each dog. At baseline, the AH interval (66±3 ms) and the average RR interval (331±17 ms) in pacing-induced AF were similar in each cohort. The increase in AH interval in normal sinus rhythm was longer after fibroblast (23±4 versus 5±5 ms; P =0.05) and fibroblast plus TGF-β1 (50±5 versus 5±5 ms; P <0.001) injections than with saline alone, with similar findings during high right atrium and distal coronary sinus pacing. The AH interval was not significantly increased after TGF-β1 injections. The AH interval was significantly longer after fibroblast plus TGF-β1 injections than with either therapy (TGF-β1 or fibroblasts) alone. The RR interval during AF was increased in dogs that received fibroblasts alone (110±36 versus −41±34 ms) and to a greater extent with the addition of TGF-β1 (294±108 versus −41±34 ms). No AV block was seen in any cohort at 4 weeks. Labeled fibroblasts that expressed vimentin were identified in all dogs that received cell injections at 4 weeks. Conclusions— AV nodal modification can be achieved with injected fibroblasts without the creation of AV block. The effect on AV node conduction is substantially enhanced by pretreatment of fibroblasts with TGF-β1. These data have therapeutic potential for the management of rapid ventricular rate during AF without pacemaker implantation.
Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population
Joshi, Nina, Johnson, Laura Lee , Wei, Wenqiang , Abnet, Christian C. , Dong, Zhi-Wei, Hawk, Ernest T. , Qiao, You‐Lin , Taylor, Philip R. , Limburg, Paul J. , Dawsey, Sanford M. , Kirsch, Ilan R. , Abnet, Christian C

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 15, 2006 | Volume: 15 | Issue: 5 | Pages: 1046-1047

10.1158/1055-9965.epi-06-0135 | PMID 16702392 Get It

Abstract Selenium is a promising cancer chemoprevention agent. A recent randomized controlled chemoprevention trial found that selenomethionine (SeMet) supplementation for 10 months favorably effected a change in esophageal dysplasia grade among participants who started the trial with mild dysplasia. To further explore the role of SeMet in this trial, we compared gene expression profiles by treatment group using Affymetrix HU 133A chips in before/after supplementation paired normal esophageal biopsies from a subset of 29 trial participants, 16 who received SeMet, and 13 who received placebo. Using P &lt; 0.001 as a cutoff, 11 differentially expressed genes were found in the SeMet supplementation group but these genes did not include either known selenoprotein genes or genes previously shown to be modulated by selenium treatment. Because the number of differentially expressed genes (n = 11) was less than expected by chance (n = 18), we concluded that SeMet supplementation had no measurable effect on gene expression in the normal squamous esophagus of these subjects with dysplasia. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1046-7)